# Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets

> **NCT07691203** · PHASE1 · COMPLETED · sponsor: **Humanis Saglık Anonim Sirketi** · enrollment: 36 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)
- Cardiovascular Diseases

## Interventions

- **DRUG:** Empagliflozin/Linagliptin/Metformin HCl Extended Release Tablet
- **DRUG:** Trijardy® XR Tablets

## Key facts

- **NCT ID:** NCT07691203
- **Lead sponsor:** Humanis Saglık Anonim Sirketi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2026-03-07
- **Primary completion:** 2026-06-16
- **Final completion:** 2026-07-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2026-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07691203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07691203, "Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCl 25 mg/5 mg/1000 mg Extended Release Tablet Versus Trijardy® XR 25 mg/5 mg/1000 mg Extended- Release Tablets". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07691203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*